1243415-10-2

Usage

Uses

Used in Pharmaceutical Industry:
5-(4-(Chloromethyl)phenyl)-3-methylisoxazole-4-carboxylic acid is used as a potential active pharmaceutical ingredient for the development of new drugs, leveraging its anti-inflammatory, antibacterial, and antifungal properties to address various medical conditions.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 5-(4-(Chloromethyl)phenyl)-3-methylisoxazole-4-carboxylic acid serves as a key compound for studying its structure-activity relationships and exploring its potential as a precursor for the synthesis of more complex and effective drug molecules.
Further research and study are necessary to fully understand the potential uses and properties of 5-(4-(Chloromethyl)phenyl)-3-methylisoxazole-4-carboxylic acid, as its exact applications and mechanisms of action in various therapeutic areas are still under investigation.

Upstream product

• 1383717-87-0 methyl 3-(4-((tert-butyldimethylsilyloxy)methyl)phenyl)-prop-2-ynoate 
• 1384485-32-8 methyl 5-(4-((tert-butyldimethylsilyloxy)methyl)phenyl)-3-methylisoxazole-4-carboxylate 
• 1384485-33-9 methyl 5-(4-(hydroxymethyl)phenyl)-3-methylisoxazole-4-carboxylate 
• 1384485-34-0 methyl 5-(4-(chloromethyl)phenyl)-3-methylisoxazole-4-carboxylate 
• 619-58-9 4-iodobenzoic acid 
• 18282-51-4 4-iodo-benzyl alcohol 
• 876-08-4 p-(chloromethyl)benzoyl chloride 

Downstream Products

• 355025-24-0 (+/-)-Ki16425 
• 354222-31-4 1-(2-chlorophenyl)ethyl 5-(4-(chloromethyl)phenyl)-3-methylisoxazol-4-ylcarbamate 

Relevant academic research and scientific papers

HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DISEASE

Heterocyclic compounds are described that are lysophosphatidic acid receptor ligands that are useful in the treatment of lysophosphatidic acid receptor-dependent diseases and conditions, including but not limited to diseases involving fibrosis, such as fibrosis of the heart, kidney, liver and lung, and scleroderma; inflammatory diseases such as diabetic nephropathy and inflammatory bowel disease; ocular diseases such as diseases involving retinal degeneration; nerve diseases such as pruritus and pain. Non-limiting examples of those compounds include (RS)-3-Cyclopropyl-2-{4-[3-methyl-4((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-benzyloxy}-propionic acid and (R)-1-(4′-{5-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-yl}-2-fluoro-biphenyl-4-yl)-cyclopropanecarboxylic acid.

Synthesis and biological evaluation of optically active Ki16425

An enantionselective synthesis of both enantiomers of Ki16425, which possesses selective LPA antagonistic activity, was achieved. The isoxazole core was constructed by a 1,3-dipolar cycloaddition of nitrile oxide with alkyne and condensation with the optically active α-phenethyl alcohol segment, which was prepared by an enantioselective reduction of arylmethylketone. Biological evaluation of both enantiomers of Ki16425 revealed that the (R)-isomer showed much higher antagonistic activity for LPA1 and LPA3 receptors.